Ocular Surface Changes in Prostaglandin Analogue-Treated Patients

Abstract EN

Glaucoma is the second leading cause of blindness globally.

Reducing intraocular pressure (IOP) has been acknowledged to be the main therapy for glaucoma.

Prostaglandin analogues (PGAs) have become the first-line therapy for patients with glaucoma due to their powerful efficacy for lowering (IOP).

However, usage of PGAs can also cause several notable side effects, including the changes in ocular surface.

The relationship between PGAs and ocular surface changes is complicated and still remains unclear.

In the present review, we summarize the recent studies of the effects of PGAs on ocular changes as well as the possible mechanisms that might provide new considerations during clinical medication.